Viatris Believes Eylea Biosimilar Candidate Is First To Reach US FDA’s Desk

As Viatris Discloses ‘Challenging’ Orencia Biosimilar Is Part Of Pipeline Again

 
• By Dean Rudge
  
Eye
Viatris developed aflibercept with Momenta, now a part of J&J • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products